Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Jiansheng Medical Technology Co. Ltd. currently has 1 pending office action in the Biotechnology & Pharmaceuticals technology area. This action is being handled by 1 distinct examiner, HOPPE, EMMA RUTH. The prosecution is occurring within 1 distinct art unit. Because there is only 1 pending office action, the busiest examiner is responsible for 1 pending action.
The concentration of the portfolio in 1 distinct art unit indicates a specific technical focus for the company's current filings. With HOPPE, EMMA RUTH assigned to the 1 pending office action, the prosecution is centralized under one individual. This means the outcome of the application depends on the interactions with this 1 distinct examiner. The data shows no distribution of work across multiple art units at this time.
Practitioners should note that the 1 pending office action represents the entirety of the active prosecution for the firm. The alignment of 1 distinct art unit with 1 distinct examiner suggests a straightforward administrative path. There are no other pending actions to compare against the 1 handled by the busiest examiner. The Biotechnology & Pharmaceuticals classification defines the current examination environment for Jiansheng Medical Technology Co. Ltd.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| HOPPE, EMMA RUTH | 1 | 40.0% | +58.3% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18425986 | Reproducible Double Unique Dual Indexing Library Construction Method for Next Generation Sequencing of microRNA Isoform and Use Thereof | HOPPE, EMMA RUTH | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18425986 | Reproducible Double Unique Dual Indexing Library Construction Method for Next Generation Sequencing of microRNA Isoform and Use Thereof | HOPPE, EMMA RUTH | — |
| Art Unit | Apps |
|---|---|
| 1683 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18425986 | Reproducible Double Unique Dual Indexing Library Construction Method for Next Generation Sequencing of microRNA Isoform and Use Thereof | HOPPE, EMMA RUTH | 1683 | §101§102§112 | Non-Final OA | — | Pending | Jan 29, 2024 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialJiansheng Medical Technology Co. Ltd. has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Emma Ruth Hoppe has the most, with 1 of Jiansheng Medical Technology Co. Ltd.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
